In Cellulo Bioorthogonal Catalysis by Encapsulated AuPd Nanoalloys: Overcoming Intracellular Deactivation
Metadatos
Mostrar el registro completo del ítemEditorial
American Chemical Society
Materia
Palladium Gold Nanoalloys Catalysis Bioorthogonal Nanoencapsulation
Fecha
2023-01-17Referencia bibliográfica
Nano Lett. 2023, 23, 804−811. [https://doi.org/10.1021/acs.nanolett.2c03593]
Patrocinador
UK Research & Innovation (UKRI); Engineering & Physical Sciences Research Council (EPSRC) EP/N021134/1; ERC (Advanced Grant CADENCE) ERC-2016-ADG-742684; European Commission European Commission Joint Research Centre H2020-MSCA-IF-2014-658833 H2020-MSCA-IF-2018-841990 H2020-MSCA-IF-2016-749299 H2020-MSCA-IF-2019-895664; Spanish Government RTI2018-099019-A-I00Resumen
Bioorthogonal metallocatalysis has opened up a
xenobiotic route to perform nonenzymatic catalytic transformations
in living settings. Despite their promising features, most metals are
deactivated inside cells by a myriad of reactive biomolecules,
including biogenic thiols, thereby limiting the catalytic functioning of
these abiotic reagents. Here we report the development of
cytocompatible alloyed AuPd nanoparticles with the capacity to
elicit bioorthogonal depropargylations with high efficiency in
biological media. We also show that the intracellular catalytic
performance of these nanoalloys is significantly enhanced by
protecting them following two different encapsulation methods.
Encapsulation in mesoporous silica nanorods resulted in augmented
catalyst reactivity, whereas the use of a biodegradable PLGA matrix increased nanoalloy delivery across the cell membrane. The
functional potential of encapsulated AuPd was demonstrated by releasing the potent chemotherapy drug paclitaxel inside cancer
cells. Nanoalloy encapsulation provides a novel methodology to develop nanoreactors capable of mediating new-to-life reactions in
cells.